Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) shareholders participated in the 2024 Annual Meeting held on Thursday, June 14, 2024, casting their votes on several key proposals, including the election of directors and ratification of the company's independent auditor.
In the election for Class III directors, N. Anthony Coles, M.D., Kathryn Guarini, Ph.D., Arthur F. Ryan, and George L. Sing were elected to serve until the 2027 Annual Meeting, with varying levels of support.
Moreover, David P. Schenkein, M.D. was elected as a Class II director until the 2026 Annual Meeting. The shareholder votes showed a strong endorsement for most nominees, with a notable divergence in votes for Arthur F. Ryan, who received a significantly lower number of votes for his election compared to the others.
The appointment of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with an overwhelming majority.
Shareholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement filed on April 25, 2024. This non-binding vote reflects shareholder satisfaction with the executive compensation strategy.
A non-binding shareholder proposal requesting simple majority voting requirements was also approved, suggesting a push from shareholders for governance changes that could make it easier to pass certain types of resolutions in the future.
The meeting, which took place at the company's headquarters in Tarrytown, New York, concluded with all proposed items addressed. The results are based on the information provided in the company's SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.